Hepion Acquires Gravitas Life Sciences in $4.25M Related-Party Deal, Names New CEO and CFO
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals acquired Gravitas Life Sciences for $4.25 million in cash and stock, gaining two clinical-stage drug candidates, and appointed new CEO and CFO from the acquired company's leadership.
Key Events · M&A and Partnerships · CTRVP
-
Acquisition of Gravitas Life Sciences
Hepion acquired all membership interests of GLS for $2,000,000 cash plus 25,000,000 shares of common stock valued at $2,250,000, plus an additional $135,000 payment.
-
Related-Party Transaction
Four Hepion directors — Vincent LoPriore, Gary Stetz, Sireesh Appajosyula, and Chase LoPriore — are officers of GLS or shareholders of its sole member; they recused themselves and the deal was approved by disinterested board members with a fairness opinion.
-
New Executive Leadership
Sireesh Appajosyula appointed CEO and Gary Stetz appointed CFO effective October 9, 2026; both have prior ties to GLS and the seller.
-
Pipeline Assets Acquired
GLS brings GV104 (nalmefene buccal film for opioid prophylaxis, FDA IND approved) and GV023 (oral infliximab for TNF-alpha inhibition, preclinical).
Analysis · CTRVP · Life Sciences
On October 6, 2026, Hepion Pharmaceuticals completed its acquisition of Gravitas Life Sciences, LLC, paying $2 million in cash and issuing 25 million shares of common stock valued at $2.25 million. The deal brings in GV104, a clinical-stage opioid antagonist with an FDA-cleared IND, and GV023, an oral infliximab candidate. This is a related-party transaction — four Hepion directors are officers of GLS or shareholders of its sole member — and it was approved by disinterested board members with a fairness opinion from Ryan Valuation Services. The company also appointed Sireesh Appajosyula as CEO and Gary Stetz as CFO, both of whom have ties to GLS and the seller. For a micro-cap company with a going-concern warning, this is a transformative event that pivots Hepion's pipeline toward immunology and inflammation assets.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.